In 2018, the pivotal placebo-controlled umbrella study with canakinumab has provided the highest level of evidence for the use of IL-1 blockers to control inflammatory symptoms in 3 diseases other than CAPS: i.e. mevalonate kinase deficiency (MKD), TNF receptor associated periodic syndrome (TRAPS), and familial Mediterranean fever (FMF) (De Benedetti et al., 2018). The gene discussed is IL1B; the disease is TNF receptor 1-associated periodic fever syndrome.